Sarcoidosis; Antimycobacterial Therapy Clinical Trial
Official title:
Investigation of the Efficacy of Antimycobacterial Therapy on Pulmonary Sarcoidosis Phase II Randomized, Double-blind, Placebo-controlled Trial
The primary purpose of this study is to investigate the efficacy and safety of oral antimycobacterial therapy in patients with confirmed progressive pulmonary sarcoidosis. We suspect that the CLEAR regimen will improve the absolute FVC percent predicted in chronic pulmonary sarcoidosis participants.
Primary Objective: To assess the efficacy and safety of oral CLEAR therapy in patients with
confirmed progressive pulmonary sarcoidosis.
Hypothesis: The CLEAR regimen will improve the absolute FVC percent predicted in chronic
pulmonary sarcoidosis participants by augmenting T cell responses through the normalization
of p56Lck expression and IL-2 production.
;